吡非尼酮在特发性肺纤维化多重疾病进展事件中的疗效
该事后分析纳入ASCEND和CAPACITY三项III期试验中接受吡非尼酮2,403 mg/d(n=623)或安慰剂(n=624)的特发性肺纤维化患者,评估12个月内多重疾病进展事件的发生率。结果显示,吡非尼酮组发生多于一次进展事件的患者比例为17.0%,低于安慰剂组的30.1%(P < .0001);进展事件后死亡发生率分别为2.1%和6.3%(P = .0002)。结论提示吡非尼酮显著减少多重进展事件及进展后死亡。
要点
- 吡非尼酮组发生多于一次疾病进展事件的患者比例显著低于安慰剂组(17.0% vs 30.1%)。
- 吡非尼酮组在发生一次或多次进展事件后的死亡比例显著低于安慰剂组(2.1% vs 6.3%)。
- 最常见的进展事件为%预测FVC下降和6MWD下降。
核心结论
- 与安慰剂相比,吡非尼酮在12个月治疗中显著降低多重疾病进展事件的发生率及进展事件后的死亡。
- 研究提示即使发生任一疾病进展事件,继续吡非尼酮治疗仍可获益。
研究设计与样本
- 事后分析纳入ASCEND(NCT01366209)和CAPACITY(NCT00287716、NCT00287729)三项III期试验中接受吡非尼酮2,403 mg/d(n=623)或安慰剂(n=624)的特发性肺纤维化患者。
- 疾病进展事件定义为%预测FVC相对下降≥10%、6MWD绝对下降≥50 m、呼吸相关住院或全因死亡。
- 评估12个月内疾病进展事件的发生率。
主要发现
- 最常见的疾病进展事件为%预测FVC下降(吡非尼酮 vs 安慰剂:202 vs 304事件)和6MWD下降(265 vs 348事件)。
- 吡非尼酮组发生多于一次进展事件的患者比例为17.0%,安慰剂组为30.1%(P < .0001)。
- 吡非尼酮组发生一次或多次进展事件后死亡的比例为2.1%,安慰剂组为6.3%(P = .0002)。
临床怎么用
- 对于接受吡非尼酮治疗的特发性肺纤维化患者,即使出现单一疾病进展事件,仍可考虑继续治疗以降低后续多重进展及死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Declines in percent predicted FVC (% predicted FVC), declines in 6-min walk distance (6MWD), and respiratory hospitalizations are events associated with disease progression and mortality in idiopathic pulmonary fibrosis. The incidence of multiple events in the same patient over 12 months of pirfenidone treatment is unknown. METHODS: Patients who received pirfenidone 2,403 mg/d (n = 623) or placebo (n = 624) in the ASCEND (study 016; NCT01366209) and CAPACITY (studies 004 and 006; NCT00287716 and NCT00287729) phase III trials were included in this post hoc analysis. Disease progression events were defined as relative decline in % predicted FVC ≥ 10%, absolute decline in 6MWD ≥ 50 m, respiratory hospitalization, or death from any cause. The incidence of disease progression events over 12 months was assessed. RESULTS: The most frequent disease progression events were declines in % predicted FVC (pirfenidone vs placebo; 202 vs 304 events) and declines in 6MWD (pirfenidone vs placebo; 265 vs 348 events). Fewer patients who received pirfenidone had more than one progression event compared with placebo (17.0% vs 30.1%; P < .0001). Death following one or more progression event occurred less frequently in the pirfenidone group than in the placebo group (2.1% vs 6.3%; P = .0002). CONCLUSIONS: Pirfenidone significantly reduced the incidence of multiple progression events and death after a progression event over 12 months of treatment compared with placebo. These findings suggest that continued treatment with pirfenidone confers a benefit despite the occurrence of any single disease progression event. TRIAL REGISTRY: ClinicalTrials.gov; Nos. NCT01366209, NCT00287716, and NCT00287729; URL: www.clinicaltrials.gov.
引用
- Nathan SD, Costabel U, Glaspole I, et al. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2018. PMID: 30472023. doi:10.1016/j.chest.2018.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。